Moleculin Biotech (MBRX) participated in a Virtual Investor “What This Means” segment. For the segment, Brian Andrew Van Tine, MD, PhD, Professor of Medicine, Washington University School of Medicine, discussed the Company’s recently announced positive topline efficacy results from its completed U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases. The MB-107 trial was a multi-center, open-label, single-arm monotherapy study that in Phase 1B determined the Maximum Tolerable Dose and Recommended Phase 2 Dose and safety of Annamycin and in Phase 2 explored the efficacy of Annamycin as a single agent for the treatment of subjects with STS lung mets for which chemotherapy was considered appropriate.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin Biotech assumed with a Buy at H.C. Wainwright
- Moleculin Biotech: Positive Clinical Trial Results and Strategic Developments Support Buy Rating
- Moleculin Biotech Hosts Key Opinion Leaders Event
- Moleculin Biotech releases KOL webcast to discuss Phase 1B/2 annamycin data
- Moleculin Biotech Stock (MBRX) Dives 10% on Clinical Trial Results